Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.

OBJECTIVES The use of IV contrast media in PET/CT can result in an overestimation of PET attenuation factors that potentially can affect interpretation. The objective of this study was to quantify the effect of IV contrast media in PET/CT and assess its impact on patients with intrathoracic malignancies. MATERIALS AND METHODS Nine patients had CTs performed with and without IV contrast media followed by (18)F-FDG PET. PET images were reconstructed using contrast-enhanced and unenhanced CT. To quantify the effect of contrast media on standardized uptake values (SUV), similar regions of interest (ROIs) were drawn on the subclavian vein, heart, liver, spleen, and site of malignancy on both CT and corresponding reconstructed PET images, and the mean and maximum values were compared. In addition, two physicians blinded to the imaging parameters that were used evaluated the reconstructed PET images to assess whether IV contrast media had an effect on clinical interpretation. RESULTS For all patient studies, the subclavian vein region on the ipsilateral side of contrast media administration had the highest increase in CT numbers with a corresponding average SUV(max) increase of 27.1%. Similarly, ROIs of the heart and at the site of malignancy showed an increase in the maximum attenuation value with a corresponding average SUV(max) increase of 16.7% and 8.4%, respectively. Other locations had relatively small attenuation value differences with a correspondingly negligible SUV variation. CONCLUSION Although there is a significant increase in SUV in regions of high-contrast concentration when contrast-enhanced CT is used for attenuation correction, this increase is clinically insignificant. Accordingly, in PET/CT, IV contrast-enhanced CT can be used in combination with the PET to evaluate patients with cancer.

[1]  Imran Zoberi,et al.  Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Gerald Antoch,et al.  Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. , 2002, AJR. American journal of roentgenology.

[3]  Jeffrey A. Fessler,et al.  3D PET reconstruction with FORE and WLS-OS-EM , 2002, 2002 IEEE Nuclear Science Symposium Conference Record.

[4]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[5]  J. Padilla,et al.  Surgical results and prognostic factors in early non-small cell lung cancer. , 1997, The Annals of thoracic surgery.

[6]  P A Salvadori,et al.  Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.

[7]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  David W Townsend,et al.  PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  D W. Townsend,et al.  Combined PET/CT Imaging in Oncology. Impact on Patient Management. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[10]  Paul Kinahan,et al.  Attenuation correction for a combined 3D PET/CT scanner. , 1998, Medical physics.

[11]  Richard L Wahl,et al.  Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. , 2003, Seminars in nuclear medicine.

[12]  D. Visvikis,et al.  CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Peters,et al.  Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[15]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[18]  M. Baccarani,et al.  Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.

[19]  G. Cook,et al.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.

[20]  M C Gilardi,et al.  PET/CT in diagnostic oncology. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[21]  Mithat Gonen,et al.  Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  N. Altorki,et al.  Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. , 2004, The Annals of thoracic surgery.

[23]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[25]  Thomas Beyer,et al.  To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Schwaiger,et al.  Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  F. Burgener,et al.  Contrast enhancement of focal hepatic lesions in CT: effect of size and histology. , 1983, AJR. American journal of roentgenology.

[29]  G. Perlmutter,et al.  Oral contrast agents in CT of the abdomen. , 1984, Radiology.

[30]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[32]  V. Bettinardi,et al.  Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  E. Pauwels,et al.  Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology , 2001, Journal of Cancer Research and Clinical Oncology.

[34]  Gerald Antoch,et al.  Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  E. Rota Kops,et al.  The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  Yuji Nakamoto,et al.  Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. , 2003, Radiology.